Scleromalacia perforans as the presenting sign for rheumatoid arthritis — a case report by Al Nawaiseh, Ibrahim et al.
56 Copyright © 2019 Via Medica, ISSN 2450–7873
CaSe report
DoI: 10.5603/oJ.2019.0009
Corresponding author: 
rashed Mustafa Nazzal, Medical University of Lublin, Lublin, poland, 20–079 Lublin, ul. Chmielna 1; tel: (+48) 690 276 143;  
e-mail: rashednazzal@yahoo.com
Scleromalacia perforans as the presenting sign 
for rheumatoid arthritis — a case report
ibrahim al nawaiseh1 , rashed Mustafa nazzal2 , Katarzyna nowomiejska2 , Mario toro2 , 
robert rejdak2
1Jordan German Eye Centre, Amman, Jordan 
2Medical University of Lublin, Lublin, Poland 
aBstraCt
Scleromalacia perforans is a rare but well-recognised extra-articular complication of rheumatoid arthritis. It is diag-
nosed usually late in the course of the disease. In this paper we present a case of scleromalacia perforans in which the 
patient was not diagnosed with rheumatoid arthritis previously; the elderly female presented with bilateral foreign 
body sensation and was found to have scleromalacia perforans, which was treated medically with a bolus dose of 
steroids followed by combined oral steroids and methotrexate, from which she developed the devastating side effect 
of thrombocytopaenia. The patient was planned for surgical therapy for the scleromalacia, but unfortunately she 
passed away during the follow-up. 
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introduCtion
Scleritis is an uncommon condition character-
ised by oedema and cellular infiltration of the entire 
thickness of the sclera. It is much less common than 
episcleritis and covers a spectrum ranging in sever-
ity from trivial self-limiting episodes to a necrotis-
ing disease that may involve adjacent tissues and 
threaten vision [1]. Scleritis has traditionally been 
broadly classified into two major categories depend-
ing on the cause: infectious and non-infectious. The 
non-infectious type is mainly immunological and is 
further subdivided into two main categories: ante-
rior and posterior. The anterior subtype can be ei-
ther necrotising or non-necrotising, with the former 
being inflammatory or non-inflammatory [2]. 
Scleromalacia perforans is a rare (4% of scleri-
tis cases) and specific type of anterior necrotising 
scleritis without inflammation, which typically af-
fects elderly women with longstanding rheumatoid 
arthritis. The use of the word ‘perforans’ is unfor-
tunate, however, because perforation of the globe 
is extremely rare as the integrity of the globe is 
maintained by a thin, but complete, layer of fibrous 
tissue [1, 2]. 
Case report
A 70-year-old female patient, not known to 
have any chronic medical illness, presented to the 
clinic complaining of recent bilateral foreign body 
sensation in both eyes, with gradual blurring of vi-
sion over the last few months. Her offspring noted 
a black spot in her whitish part of the eye develop-
ing over the previous few weeks. On examination 
of the anterior segment of both eyes (Fig. 1) were 
multiple masses were seen protruding through the 
sclera representing herniated uveal tissue with very 
thin conjunctival sheets overlying the masses with 
diffuse areas of scleral thinning all over the globe. 
A working diagnosis of anterior necrotising scleritis 
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without inflammation (scleromalacia perforans) was 
made and the patient was started immediately on 
a bolus dose of steroids (1 g intravenous methyl-
prednisolone given slowly over 45 minutes with 
cardiac monitor), and a rheumatological consulta-
tion was ordered. The rheumatologist stated that the 
patient featured a full-blown picture of rheumatoid 
arthritis (although not previously diagnosed) with 
agreement for the bolus steroid therapy to be com-
pleted in three days. During this time, a wrist X-ray 
and full serological, immunological, and chemistry 
tests were ordered. Radiology and blood panel came 
back consistent with the diagnosis of rheumatoid 
arthritis. The patient’s delayed diagnosis is mainly 
due to neglect because she was living alone and 
nobody was taking care of her. The patient was dis-
charged after three days on oral prednisolone tabs 
40 mg daily and methotrexate 15 mg once per week 
(with the addition of folic acid, omeprazole, and 
vitamin D supplement).  The patient was offered 
the surgical option (scleral patch over the herniated 
areas) and was scheduled to undergo surgery within 
a few days. Unfortunately, she then started to com-
plain of generalised fatigue, and laboratory tests im-
mediately done showed pancytopaenia, which was 
ascribed to methotrexate therapy. Methotrexate was 
stopped and the surgery was postponed. The patient 
was followed up for the following few weeks, wait-
ing for her condition to stabilise in order to proceed 
with surgical treatment for the scleromalacia. Few 
weeks later, however, she passed away from myocar-
dial infarction. 
disCussion 
The description of scleromalacia perforans is very 
old; Van Der Hoeve in 1931 drew attention to 
a condition characterised by the spontaneous ap-
pearance of scleral perforations, which he named 
scleromalacia perforans [3]. A few years later he re-
ported similar cases in which he noted that the 
disease was bilateral in most patients and began in 
the anterior sclera with yellow or greyish sub-con-
junctival nodules, associated with a gradually de-
veloping scleral necrosis, progressing to perforation 
with exposure of the uvea [4]. It is usually difficult 
to define the onset of the disease because of slow 
progression and total lack of symptoms. The change 
in scleral colour is detected by patient’s family (as in 
our case), by the patient looking in the mirror, or 
by an ophthalmologist during routine examination. 
Progression of the disease is revealed as necrotic are-
as without surrounding inflammation, and the bare 
uvea is covered only by thin layer of conjunctiva 
[1, 2]. Although the condition is classically associ-
ated with rheumatoid arthritis, it was also described 
Figure 1. Upper row showing the right eye; the lower row showing the left eye
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in other systemic vasculitis and collagen disorders 
(up to 66%) such as systemic lupus erythemato-
sus, periarteritis nodosa, Wegener’s granulomatosis, 
Behçet disease, limited scleroderma, Crohn’s dis-
ease, graft-versus-host disease, and in porphyria and 
herpes-zoster infection [5]. 
Visual loss, secondary to progression of astig-
matism (sclera and limbic and corneal changes), 
anterior uveitis, cataract (secondary to uveitis or 
steroid therapy), or glaucoma (secondary to ocular 
abnormalities or steroid therapy) is described gener-
ally in the late stages of the scleritis (in up to 60% 
of cases) [1, 2].
The main differential diagnosis for the dis-
ease is the scleral hyaline plaque, which is an oval, 
dark-greyish area located close to the insertion of 
the horizontal rectus muscles, which typically affects 
elderly patients and is innocuous [1].
Regarding the pathophysiology of the disease, 
autoimmune reaction is responsible for the vessel 
damage (type III hypersensitivity), which explains 
why immunosuppressive therapy is suggested to 
interrupt the destructive process [1, 2, 6]. 
Although scleritis may be the initial sign of 
rheumatoid disease, it usually presents more than 
10 years after the onset of arthritis. Multiple studies 
have found that patients with scleritis have more 
advanced joint disease and more extra-articular 
manifestations than do patients with rheumatoid 
arthritis without scleritis [7]. Although our patient 
did manifest a full-blown picture of rheumatoid 
arthritis, she was not diagnosed with the disease 
earlier, mainly due to neglect.
Treatment may be effective in patients with very 
early disease, but by the time most patients present, 
either no treatment is needed or it is unlikely to 
be effective. Repair of scleral perforation is very 
difficult but must be attempted otherwise phthisis 
bulbi ensues. 1
Although cyclophosphamide is known as the 
most effective drug in patients with non-infectious 
necrotising scleritis, other immunosuppressive 
drugs like methotrexate, azathioprine, cyclosporine, 
and mycophenolate mofetil are well described [1, 
2]. There are some reports describing the following: 
tumour necrosis factor inhibitors – TNF1 (etaner-
cept, infliximab), the interleukin-2 receptor blocker 
(daclizumab), the interleukin-1 receptor antagonist 
(anakinra), and the antilymphocyte medicament 
(rituximab, alemtuzumab) in managing ocular dis-
eases, including scleritis [8]. 
To detect and prevent side effects of immuno-
suppressive therapy, we recommend collaboration 
with physicians trained in the early recognition and 
management of drug-induced complication (e.g. 
haematologist, rheumatologist, internal medicine 
specialist), as was shown in our case, in which pan-
cytopaenia developed and had to be dealt with by 
the rheumatologist. 
Surgical treatment of scleromalacia is necessary 
in cases with exposed uvea to preserve the globe 
integrity. Tectonic patch grafting can be performed 
with the sclera (fresh or frozen globe or glycerine 
preserved scleral tissue), dermis, fascia lata, perios-
teum, aortic tissue, cartilage cornea, pedicle-flaps of 
conjunctiva with Müller’s muscle or tarsus, synthet-
ic material, and eventually amniotic membrane [5]. 
Patients with scleritis have higher morbidity and 
mortality rate; if left untreated with systemic medi-
cations, up to 45% of patients with scleritis and 
rheumatoid arthritis will die within three years of 
the onset of scleritis. This compares to a three-year 
mortality rate of 18% in patients with rheuma-
toid arthritis but without scleritis. Death is usually 
secondary to extra-articular vasculitis. Necrotising 
scleritis is associated with higher mortality than 
the other forms [9]. Unfortunately, this is what our 
patient suffered from, resulting in her demise with 
myocardial infarction.  
ConClusions 
Although it usually presents late in the course 
of the disease, scleromalacia perforans is sometimes 
present before the underlying disease is diagnosed 
or even manifested. Aggressive treatment with im-
munosuppression therapy is recommended to halt 
the progression of the disease, and this should be 
done in liaison with an internist who has a good 
experience in managing the resultant complications 
from these agents. 
aCKnowledgeMents
None.
stateMent oF CoMpeting interests
No competing interests.
reFerenCes
1. Jack J, Kanski BB. Clinical ophthalmology: a Systematic approach. 
elsevier 2016: 253–267.
2. american academy of ophthalmology. Basic and Clinical Science 
Course. Section 8. american academy of ophthalmology, San Fran-
sisco 2014: 202–210.
Ibrahim al Nawaiseh et al., Scleromalacia perforans as the presenting sign for rheumatoid arthritis
59www.journals.viamedica.pl/ophthalmology_journal
3. van der Hoeve J, J va. Scleromalacia perforans. Ned t Geneesk. 
1931; 75: 4733.
4. ashton N, Hobbs He. effect of cortisone on rheumatoid nodules of 
the sclera (scleromalacia perforans). Br J ophthalmol. 1952; 36(7): 
373–384, doi: 10.1136/bjo.36.7.373, indexed in pubmed: 14935113.
5. Kopacz D, Kopacz D. Scleromalacia perforans — What We Know and 
What We Can Do. J Clin exp ophthal. 2013: 9–11, doi: 10.4172/2155-
9570-s2-009.
6. Fong Lp, Sainz de la Maza M, rice Ba, et al. Immunopathology of 
scleritis. ophthalmology. 1991; 98(4): 472–479, doi: 10.1016/s0161-
6420(91)32280-2, indexed in pubmed: 1828871.
7. Ghauri MI, riaz SU, Husain a, et al. Scleromalacia perforans: a case 
report. J Med Case rep. 2018; 12(1): 155, doi: 10.1186/s13256-018-
1686-z, indexed in pubmed: 29866188.
8. Herrera-esparza r, avalos-Díaz e, Herrera-esparza r, et al. Infliximab 
treatment in a case of rheumatoid scleromalacia perforans. reuma-
tismo. 2009; 61(3): 212–215, indexed in pubmed: 19888506.
9. Foster CS, Forstot SL, Wilson La. Mortality rate in rheumatoid arthritis 
patients developing necrotizing scleritis or peripheral ulcerative kera-
titis. effects of systemic immunosuppression. ophthalmology. 1984; 
91(10): 1253–1263, doi: 10.1016/s0161-6420(84)34160-4, indexed 
in pubmed: 6514289.
